Basit öğe kaydını göster

dc.contributor.authorAlkan, Ozlem
dc.date.accessioned2019-09-30T08:26:57Z
dc.date.available2019-09-30T08:26:57Z
dc.date.issued2015
dc.identifier.issn2602-3032
dc.identifier.urihttps://dergipark.org.tr/tr/pub/cumj/issue/4206/55501
dc.identifier.urihttp://hdl.handle.net/11727/4012
dc.description.abstractHigh-grade glial tumors are the most common primary brain tumor in adults. The current standard of care for high-grade glial tumors includes surgical resection followed by combination of radiation with temazolomide treatment and adjuvant temozolomide. The Macdonald Criteria are currently the most widely used guideline for assessing response to therapy in patients with high-grade glial tumors. These are based on the size of the contrast-enhancing lesion in MR imaging. Recently, nontumoral changes in enhancement have been found. It is now clear that evaluation of gadolinium enhancement alone is not adequate to characterize tumor regression or progression. MR diffusion, MR perfusion, MR spectroscopy, and PET imaging will be important adjuncts to traditional imaging for tumor assessment. We review MR imaging findings following high-grade tumor treatment.en_US
dc.language.isoturen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectHigh-grade glial tumouren_US
dc.subjectMRen_US
dc.subjectDiffusion MRen_US
dc.subjectPerfusion MRen_US
dc.subjectMR spectroscopyen_US
dc.titleRadiological Imaging after Treatment in High-Grade Glial Tumoren_US
dc.typereviewen_US
dc.relation.journalCUKUROVA MEDICAL JOURNALen_US
dc.identifier.volume40en_US
dc.identifier.issue4en_US
dc.identifier.startpage642en_US
dc.identifier.endpage653en_US
dc.identifier.wos000363969000002en_US


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster